Relative risks of transplant outcomes in multivariate analyses adjusting for the effects of other prognostic variables
| Outcome/treatment group . | RR (95% CI) . | P . |
|---|---|---|
| TRM* | Poverall = 0.382-155 | |
| (1) No postremission therapy | 1.00 | P12 = 0.22 |
| (2) Standard-dose cytarabine | 0.71 (0.41-1.22) | P13 = 0.69 |
| (3) High-dose cytarabine | 0.89 (0.51-1.58) | P23 = 0.31 |
| Relapse† | Poverall = 0.782-155 | |
| (1) No postremission therapy | 1.00 | P12 = 0.97 |
| (2) Standard-dose cytarabine | 1.01 (0.52-1.96) | P13 = 0.66 |
| (3) High-dose cytarabine | 0.85 (0.42-1.74) | P23 = 0.49 |
| Death or relapse‡ | Poverall = 0.682-155 | |
| (1) No postremission therapy | 1.00 | P12 = 0.38 |
| (2) Standard-dose cytarabine | 0.83 (0.55-1.26) | P13 = 0.54 |
| (3) High-dose cytarabine | 0.87 (0.56-1.36) | P23 = 0.78 |
| Death2-153 | Poverall = 0.912-155 | |
| (1) No postremission therapy | 1.00 | P12 = 0.79 |
| (2) Standard-dose cytarabine | 0.94 (0.60-1.47) | P13 = 0.98 |
| (3) High-dose cytarabine | 1.01 (0.63-1.61) | P23 = 0.69 |
| Outcome/treatment group . | RR (95% CI) . | P . |
|---|---|---|
| TRM* | Poverall = 0.382-155 | |
| (1) No postremission therapy | 1.00 | P12 = 0.22 |
| (2) Standard-dose cytarabine | 0.71 (0.41-1.22) | P13 = 0.69 |
| (3) High-dose cytarabine | 0.89 (0.51-1.58) | P23 = 0.31 |
| Relapse† | Poverall = 0.782-155 | |
| (1) No postremission therapy | 1.00 | P12 = 0.97 |
| (2) Standard-dose cytarabine | 1.01 (0.52-1.96) | P13 = 0.66 |
| (3) High-dose cytarabine | 0.85 (0.42-1.74) | P23 = 0.49 |
| Death or relapse‡ | Poverall = 0.682-155 | |
| (1) No postremission therapy | 1.00 | P12 = 0.38 |
| (2) Standard-dose cytarabine | 0.83 (0.55-1.26) | P13 = 0.54 |
| (3) High-dose cytarabine | 0.87 (0.56-1.36) | P23 = 0.78 |
| Death2-153 | Poverall = 0.912-155 | |
| (1) No postremission therapy | 1.00 | P12 = 0.79 |
| (2) Standard-dose cytarabine | 0.94 (0.60-1.47) | P13 = 0.98 |
| (3) High-dose cytarabine | 1.01 (0.63-1.61) | P23 = 0.69 |
RR, relative risk; CI, confidence interval.
Other significant covariates were age older than 30 years at transplantation (RR = 1.90, 95% CI, 1.28-2.85, P= .002); year of transplantation 1991 or later (RR = 0.56, 95% CI, 0.36-0.85, P = .007); and Karnofsky performance score ≥90 (RR = 0.52, 95% CI, 0.30-0.90, P = .020).
Another significant covariate for relapse was female sex (RR = 0.59, 95% CI, 0.38-0.93, P = .024).
Other significant covariates for death or relapse were age older than 30 years at transplantation (RR = 1.55, 95% CI, 1.15-2.08,P = .004); year of transplantation 1991 or later (RR = 0.68, 95% CI, 0.50-0.92, P = .013); Karnofsky performance score ≥ 90 (RR = 0.63, 95% CI, 0.41-0.97, P = .037); and female sex (RR = 0.68, 95% CI, 0.51-0.92, P = .011).
Other significant covariates for death were age older than 30 years at transplantation (RR = 1.67, 95% CI, 1.24-2.27,P = .001); year of transplantation 1991 or later (RR = 0.65, 95% CI, 0.47-0.89, P = .008); and female sex (RR = 0.73, 95% CI, 0.54-0.99, P = .045).
Two degrees of freedom.